» Articles » PMID: 25310094

Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived from Leishmania Major Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps Toward Polytope Vaccine

Overview
Journal PLoS One
Date 2014 Oct 14
PMID 25310094
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are several reports demonstrating the role of CD8 T cells against Leishmania species. Therefore peptide vaccine might represent an effective approach to control the infection. We developed a rational polytope-DNA construct encoding immunogenic HLA-A2 restricted peptides and validated the processing and presentation of encoded epitopes in a preclinical mouse model humanized for the MHC-class-I and II.

Methods And Findings: HLA-A*0201 restricted epitopes from LPG-3, LmSTI-1, CPB and CPC along with H-2Kd restricted peptides, were lined-up together as a polytope string in a DNA construct. Polytope string was rationally designed by harnessing advantages of ubiquitin, spacers and HLA-DR restricted Th1 epitope. Endotoxin free pcDNA plasmid expressing the polytope was inoculated into humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice intramuscularly 4 days after Cardiotoxin priming followed by 2 boosters at one week interval. Mice were sacrificed 10 days after the last booster, and splenocytes were subjected to ex-vivo and in-vitro evaluation of specific IFN-γ production and in-vitro cytotoxicity against individual peptides by ELISpot and standard chromium-51 (51Cr) release assay respectively. 4 H-2Kd and 5 HLA-A*0201 restricted peptides were able to induce specific CD8 T cell responses in BALB/C and HLA-A2/DR1 mice respectively. IFN-γ and cytolytic activity together discriminated LPG-3-P1 as dominant, LmSTI-1-P3 and LmSTI-1-P6 as subdominant with both cytolytic activity and IFN-γ production, LmSTI-1-P4 and LPG-3-P5 as subdominant with only IFN-γ production potential.

Conclusions: Here we described a new DNA-polytope construct for Leishmania vaccination encompassing immunogenic HLA-A2 restricted peptides. Immunogenicity evaluation in HLA-transgenic model confirmed CD8 T cell induction with expected affinities and avidities showing almost efficient processing and presentation of the peptides in relevant preclinical model. Further evaluation will determine the efficacy of this polytope construct protecting against infectious challenge of Leishmania. Fortunately HLA transgenic mice are promising preclinical models helping to speed up immunogenicity analysis in a human related mouse model.

Citing Articles

New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine.

Oliveira D, Zaldivar M, Goncalves A, Resende L, Mariano R, Pereira D Vaccines (Basel). 2024; 12(3).

PMID: 38543905 PMC: 10975552. DOI: 10.3390/vaccines12030271.


Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T Cells That Trigger Protection against Experimental Visceral Leishmaniasis.

Brito R, Ruiz J, Cardoso J, Ostolin T, Reis L, Mathias F Vaccines (Basel). 2020; 8(2).

PMID: 32471081 PMC: 7349981. DOI: 10.3390/vaccines8020252.


How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?.

Lima-Junior J, Morgado F, Conceicao-Silva F Cells. 2017; 6(4).

PMID: 28961208 PMC: 5755491. DOI: 10.3390/cells6040031.


A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Infection.

Alves-Silva M, Nico D, Morrot A, Palatnik M, Palatnik-de-Sousa C Front Immunol. 2017; 8:100.

PMID: 28280494 PMC: 5322207. DOI: 10.3389/fimmu.2017.00100.


Designing and Cloning Molecular Constructs to Knock Out e (GPI12) Gene in (MRHO/IR/75/ER).

Almani P, Sharifi I, Kazemi B, Babaei Z, Bandehpour M, Salari S Iran J Parasitol. 2017; 11(4):448-462.

PMID: 28127356 PMC: 5251173.


References
1.
Muller I, Kropf P, Louis J, Milon G . Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major. Infect Immun. 1994; 62(6):2575-81. PMC: 186547. DOI: 10.1128/iai.62.6.2575-2581.1994. View

2.
Mougneau E, Bihl F, Glaichenhaus N . Cell biology and immunology of Leishmania. Immunol Rev. 2011; 240(1):286-96. DOI: 10.1111/j.1600-065X.2010.00983.x. View

3.
Russo D, Chakrabarti P, Higgins A . Leishmania: naive human T cells sensitized with promastigote antigen and IL-12 develop into potent Th1 and CD8(+) cytotoxic effectors. Exp Parasitol. 1999; 93(3):161-70. DOI: 10.1006/expr.1999.4452. View

4.
Gurunathan S, Stobie L, Prussin C, Sacks D, Glaichenhaus N, Iwasaki A . Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol. 2000; 165(2):915-24. DOI: 10.4049/jimmunol.165.2.915. View

5.
Schroeder J, Aebischer T . Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin. 2011; 7 Suppl:10-5. DOI: 10.4161/hv.7.0.14556. View